Cyproteronacetat und Meningeomrisiko

Ostrom QT, Gittleman H, Xu J et al (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro-Oncology 18(5):v1–v75 Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99:307–314 Lin DD, Lin JL, Deng XY, Li W, Li DD, Yin B, Lin J, Zhang N, Sheng HS (2019) Trends in intracranial meningioma incidence in the United States, 2004–2015. Cancer Med 8(14):6458–6467 Ter Wengel PV, Martin E, Gooren L, Den Heijer M, Peerdeman SM (2016) Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature. Andrologia 48(10):1130–1137 Hatiboglu MA, Cosar M, Iplikcioglu AC, Ozcan D (2008) Sex steroid and epidermal growth factor profile of giant meningiomas associated with pregnancy. Surg Neurol 69(4):356–363 Smith JS, Quiñones-Hinojosa A, Harmon-Smith M, Bollen AW, McDermott MW (2005) Sex steroid and growth factor profile of a meningioma associated with pregnancy. Can J Neurol Sci 32(1):122–127 Schoenberg BS, Christine BW, Whisnant JP (1975) Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 25(8):705–712 Rao G, Giordano SH, Liu J, McCutcheon IE (2009) The association of breast cancer and meningioma in men and women. Neurosurgery 65(3):483–489 Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MW, Thijssen JH (2000) Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids 65(10–11):795–800 Gabos S, Berkel J (1992) Meta-analysis of progestin and estrogen receptors in human meningiomas. Neuroepidemiology 11(4–6):255–260 Qi ZY, Shao C, Huang YL, Hui GZ, Zhou YX, Wang Z (2013) Reproductive and exogenous hormone factors in relation to risk of meningioma in women: a meta-analysis. PLoS One 8(12):e83261 Benson VS, Pirie K, Green J, Bull D, Casabonne D, Reeves GK, Beral V (2019) Hormone replacement therapy and incidence of central nervous system tumours in the million women study. Neuro-Oncology 21(4):498–507 Muskens IS, Wu AH, Porcel J, Cheng I, Le Marchand L, Wiemels JL, Setiawan VW (2019) Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the multiethnic cohort. Neuro-Oncology 21(4):498–507 Andersen L, Friis S, Hallas J, Ravn P, Schrøder HD, Gaist D (2013) Hormone replacement therapy increases the risk of cranial meningioma. Eur J Cancer 49(15):3303–3310 Froelich S, Dali-Youcef N, Boyer P, Kehrli P, Maitrot D, Auwerx J, Schlienger JL (2008) Does cyproterone acetate promote multiple meningiomas? EJEA 16:P158 Gil M, Oliva B, Timoner J, Maciá MA, Bryant V, de Abajo FJ (2011) Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol 72(6):965–968 Cea-Soriano L, Blenk T, Wallander MA, Rodríguez LA (2012) Hormonal therapies and meningioma: is there a link? Cancer Epidemiol 36(2):198–205 Schildkraut JM, Calvocoressi L, Wang F et al (2014) Endogenous and exogenous hormone exposure and the risk of meningioma in men. J Neurosurg 120(4):820–826 Giraldi L, Hansen JV, Wohlfahrt J et al (2019) Male hormone-interfering drugs and meningioma development. Neurooncol Adv 1(1):vdz46 Sys C, Kestelyn P (2015) Unilateral proptosis and blindness caused by meningioma in a patient treated with cyproterone acetate. GMS Ophthalmol Cases 5:Doc5 Bernat AL, Bonnin S, Labidi M, Aldahak N, Bresson D, Bouazza S, Froelich S (2018) Regression of giant olfactory groove meningioma and complete visual acuity recovery after discontinuation of cyproterone acetate. J Ophthalmic Vis Res 13(3):355–358 Raj R, Korja M, Koroknay-Pál P, Niemelä M (2018) Multiple meningiomas in two male-to-female transsexual patients with hormone replacement therapy: a report of two cases and a brief literature review. Surg Neurol Int 9:109 Portet S, Naoufal R, Tachon G, Simonneau A, Chalant A, Naar A, Milin S, Bataille B, Karayan-Tapon L (2019) Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment. Neurooncol Adv 1(1):vdz3 Weill A et al (2019) Exposition prolongée à de fortes doses d’acétate de cyprotérone et risque de méningiome chez la femme. https://www.ansm.sante.fr/var/ansm_site/storage/original/application/b632fbd0387cd9e80a8312469ed52d2a.pdf. Zugegriffen: 04.07.2020 BfArM (2020) Rote-Hand-Brief zu Cyproteronacetat: Anwendungsbeschränkungen aufgrund des Risikos für Meningeome. www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2020/rhb-cyproteron.pd. Zugeriffen: 11.07.2020 EMA (2020) Assessment report. Referral under article 31 of directive 2001/83/EC resulting from pharmacovigilance data. INN/active substance: cyproterone. www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-prac-assessment-report_en.pdf. Zugegriffen: 11.07.2020